The first participant has been dosed in a Phase 1/2 clinical trial evaluating VTx-002, an experimental gene therapy developed by VectorY Therapeutics for amyotrophic lateral sclerosis (ALS), the company announced February 9, 2026.
The trial, dubbed PIONEER-ALS, is a multicenter, open-label, dose-escalation study designed to assess the safety, tolerability, and potential efficacy of VTx-002 in adults with ALS. The initial dosing occurred at the Sean M. Healey & AMG Center for ALS at Mass General Brigham, a leading treatment and research facility for neurodegenerative diseases.
VTx-002 is a first-in-class vectorized antibody engineered to target TDP-43 pathology, a hallmark of ALS. The therapy utilizes an adeno-associated virus to deliver genetic information directly to nerve cells in the brain and spinal cord, prompting them to produce antibodies that clear toxic TDP-43 protein aggregates believed to contribute to nerve cell damage. The treatment recently received Fast Track designation from the U.S. Food and Drug Administration, intended to expedite its development and review.
“ALS is a fatal neurodegenerative disease with no cure and only limited symptomatic treatment options available,” said Olga Uspenskaya-Cadoz, M.D., Ph.D., and chief medical officer of VectorY. “The initiation of dosing in the PIONEER-ALS trial is a significant milestone for VectorY as we strive to transform the neurodegenerative disease landscape with novel disease-modifying approaches. This trial marks the first ever clinical evaluation of a therapy designed to holistically target TDP-43 pathology in ALS, and thereby reduce TDP-43 aggregation, correct mis-splicing abnormalities, and restore normal nuclear function.”
The PIONEER-ALS trial is expected to enroll up to 12 adults with ALS across sites in the U.S., Europe, and the U.K. Participants will be assigned to receive one of two dose levels of VTx-002 via injection into the cisterna magna. Researchers will monitor safety, tolerability, and pharmacokinetic data, as well as exploratory efficacy measures, including neurofilament light chain and TDP-43 pathway-related biomarkers, and clinical assessments like ALSFRS-R, slow vital capacity, and hand-held dynamometry.
